Literature DB >> 12831992

Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron.

Atsushi Obata1, Shingo Kasamatsu, Deborah W McCarthy, Michael J Welch, Hideo Saji, Yoshiharu Yonekura, Yasuhisa Fujibayashi.   

Abstract

(64)Cu is a useful radiotracer for positron emission tomography (PET) and a promising radiotherapy agent for the treatment of cancer. Recently, (64)Cu-labeled radiopharmaceuticals were reported to be useful for internal radiation therapy as well as PET monitoring of tumors.(64)Cu was produced at the Fukui Medical University's cyclotron using twelve MeV proton irradiation and the (64)Ni(p,n) (64)Cu nuclear reaction. A (64)Ni target was electroplated on a gold disk at a thickness of 50 to > 100 microm. Electroplating was performed at 2.5 V, at currents between 5-15 mA, and was completed in 12-24 hr. The (64)Ni target was bombarded with a 50 +/- 3 microA proton current. After bombardment, (64)Cu was separated from the (64)Ni target and other contaminants using an anion exchange column. Target (64)Ni was recovered and re-used. The yield of (64)Cu was 0.6 to > 3.0 mCi/microA*h, and averaged 1.983 mCi/microA*h. The radionuclidic purity of (64)Cu was over 99%. In this study, we obtained sufficient qualities and quantities of (64)Cu for therapeutic application and dose monitoring using PET using an ultra-small cyclotron.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12831992     DOI: 10.1016/s0969-8051(03)00024-6

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  27 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides.

Authors:  Zhengxin Cai; Barbara T Y Li; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Dalton Trans       Date:  2015-03-07       Impact factor: 4.390

3.  Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Authors:  Sibaprasad Bhattacharyya; Manish Dixit
Journal:  Dalton Trans       Date:  2011-05-03       Impact factor: 4.390

4.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

5.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

6.  A comparison of PET imaging characteristics of various copper radioisotopes.

Authors:  Heather Ann Williams; Simon Robinson; Peter Julyan; Jamal Zweit; David Hastings
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

Review 7.  Production of radiometals in liquid targets.

Authors:  Sergio J C do Carmo; Peter J H Scott; Francisco Alves
Journal:  EJNMMI Radiopharm Chem       Date:  2020-01-10

Review 8.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

9.  PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Authors:  Mathew L Thakur; Mohan R Aruva; Jean Gariepy; Paul Acton; Satish Rattan; Shyam Prasad; Eric Wickstrom; Abass Alavi
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

10.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Authors:  Carolyn J Anderson; Riccardo Ferdani
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.